Pregled bibliografske jedinice broj: 1195707
Changes of recommended anticoagulation therapy in patients with atrial fibrillation and high thrombotic risk: long-term follow-up data from two hospital centers
Changes of recommended anticoagulation therapy in patients with atrial fibrillation and high thrombotic risk: long-term follow-up data from two hospital centers // Expert review of cardiovascular therapy, 19 (2021), 9; 857-863 doi:10.1080/14779072.2021.1962293 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1195707 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Changes of recommended anticoagulation therapy in
patients with atrial fibrillation and high
thrombotic risk: long-term follow-up data from two
hospital centers
Autori
Hadžibegović, Irzal ; Jurin, Ivana ; Letilović, Tomislav ; Radonić, Vedran ; Jurin, Hrvoje ; Mikšić, Štefica ; Lucijanić, Marko
Izvornik
Expert review of cardiovascular therapy (1477-9072) 19
(2021), 9;
857-863
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
atrial fibrillation ; anticoagulation ; optimal dosing ; therapy switch ; thromboembolic protection.
Sažetak
Aim : To investigate changes of anticoagulation therapy in patients with atrial fibrillation (AF) and high thrombotic risk.Methods : We retrospectively analyzed 1061 patients with non- valvular AF and indication for anticoagulation therapy referred in a period from 2013 to 2018 and followed-up for a median time of 38 months.Results : Therapy change occurred in 206 (19.5%) patients (195 switches and 11 permanent discontinuations). Only 37% of patients on warfarin had optimal dosing and their duration of therapy was significantly shorter compared to direct oral anticoagulants (DOACs ; (adjusted HR 1.21, 95% CI 1.09-1.37). Therapy change occurred in only 33% of patients with poorly controlled warfarin, and in only 24% of patients that experienced a thrombotic event while taking warfarin. Optimal dosing was an independent factor for any therapy change during follow-up, irrespective of type of anticoagulant drug at baseline. DOAC swapping occurred in 39% of all DOAC to DOAC switches, with one bleeding event and no thrombotic events documented after a DOAC swap.Conclusion : High risk patients with AF rarely discontinue anticoagulation therapy. The need for therapy change should be emphasized in patients with non-optimal dosing, and in patients that experience thrombotic events while taking warfarin.
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur",
Medicinski fakultet, Zagreb,
Klinička bolnica "Dubrava"
Profili:
Štefica Mikšić
(autor)
Marko Lucijanic
(autor)
Irzal Hadžibegović
(autor)
Tomislav Letilović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus
- MEDLINE